Efficacy and safety of lobeglitazone versus sitagliptin as an add‐on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.

Kim, Sin Gon; Kim, Kyoung Jin; Yoon, Kun Ho; Chun, Sung Wan; Park, Kyong Soo; Choi, Kyung Mook; Lim, Soo; Mok, Ji‐Oh; Lee, Hyoung Woo; Seo, Ji A.; Cha, Bong‐Soo; Kim, Mi Kyung; Shon, Ho Sang; Choi, Dong Seop; Kim, Doo Man

We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add‐on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between‐group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non‐inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add‐on to metformin in terms of efficacy and safety.

SITAGLIPTIN; TYPE 2 diabetes; METABOLIC syndrome; GLYCOSYLATED hemoglobin; LIPID metabolism

Diabetes, Obesity & Metabolism, 2020, Vol 22, Issue 10, p1869

1462-8902

Academic Journal

10.1111/dom.14085